Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000 Mar; 18(6):1301-8.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials, Phase II as Topic
Cohort Studies
Cytarabine
Female
Humans
Interferon-alpha
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Logistic Models
Male
Mental Disorders
Middle Aged
Multivariate Analysis
Neurotoxicity Syndromes
Recombinant Proteins
Regression Analysis
Risk Factors

authors with profiles

Richard A. Larson